Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions

Bose, Katrin; Franck, Caspar; Müller, Meike N; Canbay, Ali; Link, Alexander; Venerito, Marino

doi:10.1155/2017/5651903

Cited by 10 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, FLOT can be considered the new standard of care in the perioperative treatment of patients with resectable GC or AEG with a good performance status. In particular, as both FLOT and ECF are platinum/fluoropyrimidine‐based triplets and taking into account the data from the OE 05 trial, the advantage of FLOT over ECF/ECX appears to be mainly based on the higher effectiveness of docetaxel compared to epirubicin …”

Section: Gastric Cancer: Treatmentmentioning

confidence: 99%

Gastric cancer: epidemiology, prevention, and therapy

et al. 2018

Self Cite

View full text Add to dashboard Cite

Gastric cancer (GC) is still the third leading cause of cancer death in both sexes worldwide. Helicobacter pylori infection is the most important risk factor for GC and, in spite of the consistent trend of a decreasing incidence, in 2015 approximately 4.4 billion individuals-more than half the world's population-were infected with H. pylori. The birth cohort pattern of decreased H. pylori infection reported in a systematic review contributes to explain the declining GC mortality in Japan. Current trends in estimated annual percentage change of GC incidence foreshadow expected reversals in both falling incidence and male predominance among US non-Hispanic whites. Combining serum pepsinogen 1 and H. pylori serology was shown to be useful for GC risk stratification in a Finnish population. Gastritis staging by operative link on gastritis assessment was confirmed to be reliable in predicting GC risk in a large prospective study. In a randomized trial from South Korea, H. pylori eradication therapy significantly reduced the rates of metachronous GC in patients who received curative endoscopic resection for early GC. A study based on a territory-wide health care database of the Hong Kong Hospital Authority showed that aspirin use is associated with a reduced GC risk. Another study based on the same database showed that proton pump inhibitors increase GC risk, but methodological biases have most likely acted as confounders. Confirmatory data on the role of endoscopic submucosal dissection in patients with early GC have been published. The phase III FLOT4 trial has shown that the FLOT triplet regimen (docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil) improves the outcome of patients with GC and locoregional disease as compared to the ECF triplet (epirubicin, cisplatin, and 5-fluorouracil). In the phase III ATTRACTION-2 trial, nivolumab was shown to be an effective treatment option with a relative safe profile for heavily pretreated patients with advanced GC.

show abstract

Section: Gastric Cancer: Treatmentmentioning

confidence: 99%

Gastric cancer: epidemiology, prevention, and therapy

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…The FLOT regimen significantly increased rates of curative surgery and prolonged median PFS (18 vs 30 months) and median OS (35 vs 50 months) as compared to the ECF/ECX (epirubicin/cisplatin/oral capecitabine) regimen in Western countries, S‐1 is licensed in advanced gastric cancer in combination with cisplatin only . However, due to the pharmacogenomic differences in Western patients, the maximum tolerated dose of S‐1 with cisplatin is lower than that in Asian patients . Accordingly, FLOT can be considered the new standard care in perioperative treatment for European patients with resectable gastric and gastroesophageal junction adenocarcinoma.…”

Section: Neoadjuvant (Perioperative) Chemotherapymentioning

confidence: 99%

Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer

Kanaji

Suzuki

Matsuda

et al. 2018

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Gastrectomy with D2 lymph node dissection has become the global standard procedure for locally advanced gastric cancer to maximally reduce locoregional recurrence. In East Asia, based on the evidence of the ACTS‐GC and the CLASSIC trials, postadjuvant chemotherapy with S‐1 monotherapy or capecitabine and oxaliplatin after curative D2 gastrectomy is the current standard strategy. However, approximately 20% to 30% of patients still develop distant recurrence even after these postadjuvant chemotherapies, especially in those with pathological stage III disease. This review summarizes recent (2008‐2018) evidence on the benefits of adjuvant therapy for locally advanced gastric cancer. JACRO GC‐07, a Phase III trial, recently showed a superior 3‐year recurrence‐free survival of the S‐1 plus docetaxel regimen in comparison to S‐1 monotherapy for patients with pathological stage III gastric cancer after curative D2 gastrectomy. With regard to recent new evidence on neoadjuvant strategy, JCOG0501, a Phase III trial, did not show any superiority in 3‐year overall survival (OS) of additional neoadjuvant chemotherapy with S‐1/cisplatin over postadjuvant S‐1 monotherapy in scirrhous type gastric cancer. Further clinical trials of neoadjuvant chemotherapy are ongoing to improve the poor prognosis for gastric cancer with extensive lymph node metastases. These trials could lead to new evidence for improved treatment of gastric cancer in the near future.

show abstract

“… Relative proportion of H. pylori seropositivity in subjects presented in emergency department (Wex et al 2011) [ 12 ] or in blood donors (Franck et al 2017) [ 31 ]. H. pylori positivity status was defined in all three studies using similar criteria: anti- H. pylori -IgG+ and/or anti-CagA-IgG+.…”

Section: Figurementioning

confidence: 99%

Helicobacter Pylori Serology in Relation to Hepatitis C Virus Infection and IL28B Single Nucleotide Polymorphism

Gutwerk

Wex

Stein

et al. 2018

JCM

Self Cite

View full text Add to dashboard Cite

The aim of the study was to evaluate the serological rate of Helicobacter pylori (H. pylori) infection in patients with chronic hepatitis C virus (HCV) infection and determine any correlations with liver damage and IL28B single-nucleotide polymorphism (SNP). One hundred eighty-nine patients with chronic HCV infection were included in the study, and H. pylori status was defined based on anti-H. pylori-IgG or anti-CagA-IgG antibodies using enzyme-linked immunosorbent assay (ELISA). Liver damage was assessed using histology or transient elastography. IL28B C/T polymorphism (rs12979860) was evaluated in circulating blood cells using a PCR-based restriction fragment length polymorphism assay. Overall H. pylori serology was positive in 38.1% of our HCV-infected subjects. Among those, the anti-CagA-IgG positivity rate was 43.1% and was within the range of previously described populations of the same region. Highest prevalence of H. pylori was found in patients between 31 and 40 years compared to other age subgroups. The seropositivity rate was higher in the non-cirrhotic group than the cirrhotic one (45.4% vs. 20.0%, p < 0.05). No difference was found in IL28B genotype between H. pylori-positive and -negative cohorts. However, we observed a trend for the lower anti-CagA-IgG expression level in relation to the IL28B T-allele. Our results do not support an association between HCV and H. pylori infection. Whether IL28B SNP has a functional role in modulation of serological response to H. pylori CagA needs further investigation.

show abstract

Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions

Cited by 10 publications

References 39 publications

Gastric cancer: epidemiology, prevention, and therapy

Gastric cancer: epidemiology, prevention, and therapy

Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer

Helicobacter Pylori Serology in Relation to Hepatitis C Virus Infection and IL28B Single Nucleotide Polymorphism

Contact Info

Product

Resources

About